Spero Therapeutics Secures $105 Million Royalty Financing Deal With Healthcare Royalty

RTTNews··Read original
3▲1 ▼0Impact / 5
Summary · why it matters

Spero Therapeutics announced a $105 million non-recourse non-dilutive royalty financing transaction with affiliates of Healthcare Royalty, a royalty acquisition company majority owned by KKR & Co. Inc. The proceeds will primarily support advancement of Spero's immunology drug candidate SP001. Healthcare Royalty will provide the $105 million payment at closing, net of original issue discount and applicable fees, in exchange for rights to a portion of future milestone and royalty payments from sales of Utebzi owed by GSK. Healthcare Royalty will receive quarterly principal and interest payments derived solely from those GSK payments until the loan balance is repaid, after which Spero will retain 35% of subsequent GSK payments related to Utebzi sales. Following the transaction, Spero updated its cash runway guidance into the second half of 2029. In pre-market trading on NasdaqGS, Spero shares fell 6.79 percent to $2.03.

Impact on assets 3

Health Care▲
Spero Therapeutics Inc
SPRO
▲ PositiveCapitalrelevance

Spero Therapeutics announced a $105 million non-dilutive royalty financing deal with Healthcare Royalty, extending cash runway to H2 2029.

Biotech & Genomic Medicine▲
Aging Population▲

Off-coverage companies 1

HealthCare Royaltyi
Private▲ PositiveCapitalrelevance

HealthCare Royalty enters a royalty financing agreement with Spero, acquiring rights to future milestone and royalty payments from GSK.